ChemoCentryx

ChemoCentryx, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer primarily focused on orphan and rare diseases. ChemoCentryx is the only company focused exclusively on small molecule therapeutics that target the chemoattractant system, a biological network that regulates inflammation via a collection of secreted chemokine molecules, or ligands, and their specific cell surface receptors. ChemoCentryx has generated a broad portfolio of clinical and preclinical-stage programs, each targeting distinct chemokine and chemoattractant receptors. We are passionate about the science underlying the chemoattractant network and about the opportunity it holds to provide better medicines for better lives.